Browsing Tag
Comirnaty
6 posts
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
Pfizer Q3 2025 earnings beat forecasts as non-COVID drug sales lift margins and EPS guidance
Find out how Pfizer beat Q3 2025 earnings forecasts and raised full-year EPS guidance as non-COVID drugs and cost savings drove profit growth.
Can seasonal COVID‑19 shots follow the flu vaccine playbook—and will Americans comply in 2025?
Will Americans embrace annual COVID-19 shots like flu vaccines? Explore how LP.8.1, FDA guidance, and public trust shape the 2025 rollout.
Pfizer and BioNTech secure FDA approval for LP.8.1-adapted COMIRNATY vaccine for high-risk groups
Pfizer and BioNTech's LP.8.1-adapted COVID-19 vaccine gets FDA approval for high-risk groups. Find out what this means for the 2025–2026 rollout season.
Pfizer beats Q2 2025 earnings expectations and raises profit forecast, but long-term growth questions persist
Pfizer beats Q2 2025 estimates and raises profit guidance, but patent expirations and pricing pressures keep long-term growth questions on the table.
Pfizer stuns Wall Street with booming Q3 earnings and new guidance boost
Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising…